IL17A and Arthritis: MPCs injected intravenously to sheep with collagen-induced joint inflammation was demonstrated to decrease cartilage erosions, synovial stromal cell activation, angiogenesis, and plasma levels of activin A and IL-17A, confirming that systemic administration of these cells can modulate both local joint and systemic inflammation [32].